search
Back to results

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Primary Purpose

Solid Tumor, Breast Cancer, Pancreatic Cancer

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
SON-DP
Sponsored by
Qurgen Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Solid Tumor focused on measuring SON-DP, Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Signed written informed consent; Male or female participants aged ≥ 18 years; For Phase Ia: Participants with histologic diagnosis and confirmed solid tumor; For Phase Ib: Participants with one of the four tumor types: breast cancer, pancreatic cancer, ovarian cancer or colorectal cancer; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at study entry and an estimated life expectancy of at least 3 months; Agree to the placement of drug infusion venous access; For high dose group, agree for two biopsies, one at screening and one at 1st week of cycle 2; Adequate hematological function; Adequate hepatic/renal function; Acceptable coagulation function; Recovered from prior treatment Adverse Effect; Effective contraception for female participant with child bearing potential participants and sexually active male participants. Exclusion Criteria: Participation in investigational study within 2 weeks or 5 half-lives, whichever is shorter of the first dose of study treatment. Impaired cardiac function or clinically significant cardiac disease. History of stroke or clinically significant intracranial hemorrhage within 6 months before first dose of study drug. Malignant disease, other than that being treated in this study. Anticancer therapy within 5 half-lives or 2 weeks (whichever is longer) prior to study entry. Active infection requiring intravenous systemic antibiotic or antiviral therapy within 14 days prior to the first dose of study drug. Major surgery within 4 weeks of the first dose of study treatment. Any medical condition that would, in the Investigator's judgment, prevent the participant's participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results.

Sites / Locations

  • Banner MD Anderson Cancer Center (BMDACC)
  • Henry Ford Health System
  • Carolina BioOncology InstituteRecruiting
  • Stephenson Cancer Center, University of Oklahoma
  • MD Anderson Cancer Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm 11

Arm 12

Arm 13

Arm 14

Arm 15

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Dose escalation, Cohort 1

Dose escalation, Cohort 2

Dose escalation, Cohort 3

Dose escalation, Cohort 4

Dose escalation, Cohort 5

Dose escalation, Cohort 6

Dose escalation, Cohort 7

Dose escalation, Cohort 8

Dose escalation, Cohort 9

Dose escalation, Cohort 10

Dose escalation, Cohort 11

Dose expansion, Arm 1

Dose expansion, Arm 2

Dose expansion, Arm 3

Dose expansion, Arm 4

Arm Description

Drug: SON-DP 1 participant or 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 1 at dose level 1 once per week in 28-day cycle, for up to 6 cycles.

Drug: SON-DP 1 participant or 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 2 at dose level 2 once per week in 28-day cycle, for up to 6 cycles.

Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 3 at dose level 3 once per week in 28-day cycle, for up to 6 cycles.

Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 4 at dose level 4 once per week in 28-day cycle, for up to 6 cycles.

Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 5 at dose level 3 twice per week in 28-day cycle, for up to 6 cycles.

Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 6 at dose level 4 twice per week in 28-day cycle, for up to 6 cycles.

Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 7 at dose level 5 either once per week or twice per week (FINAL SCHEDULE) in 28-day cycle, for up to 6 cycles.

Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 8 at dose level 6 either once per week or twice per week (FINAL SCHEDULE) in 28-day cycle, for up to 6 cycles.

Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 9 at dose level 7 either once per week or twice per week (FINAL SCHEDULE) in 28-day cycle, for up to 6 cycles.

Drug: SON-DP Up to 12 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion at the RP2D-1 dose level using either once per week or twice per week (FINAL SCHEDULE), for up to 6 cycles.

Drug: SON-DP Up to 12 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level using either once per week or twice per week (FINAL SCHEDULE), for up to 6 cycles.

Drug: SON-DP Up to 18 participants with breast cancer will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level using the Final Schedule, for up to 6 cycles.

Drug: SON-DP Up to 18 participants with pancreatic cancer will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level, for up to 6 cycles.

Drug: SON-DP Up to 18 participants with ovarian cancer will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level, for up to 6 cycles.

Drug: SON-DP Up to 18 participants with colorectal cancer will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level, for up to 6 cycles.

Outcomes

Primary Outcome Measures

Number of participants with AEs, with abnormal vital signs, abnormal ECG readings, abnormal clinical laboratory tests results, abnormal physical examinations and abnormal ECOG performance status.
MTD (Maximum tolerable dose) / RP2D (Recommended dose for phase II)

Secondary Outcome Measures

ORR
Objective response rate (ORR)
DCR
Disease control rate (DCR)
DOR
Duration of response (DoR)
TTP
Time-to-event endpoints of time to disease progression (TTP)
PFS
Progression-free survival (PFS)
OS
Overall Survival (OS)
Cmax
Maximum serum concentration (Cmax) of 3 proteins from SON-DP will be investigated.
Tmax
Time to maximum serum concentration (Tmax) of 3 proteins from SON-DP will be investigated.
T1/2
Half-life (T1/2) of 3 proteins from SON-DP will be investigated.
AUC0-t
AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration.
CL
Clearance (CL) in the serum of 3 proteins from SON-DP per unit of time will be investigated.

Full Information

First Posted
July 19, 2023
Last Updated
August 4, 2023
Sponsor
Qurgen Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05989724
Brief Title
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Official Title
A First-in-Human (FIH), Open-Label, Phase Ia/Ib Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-DP in Participants With Relapsed/Metastatic Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 2023 (Anticipated)
Primary Completion Date
September 2025 (Anticipated)
Study Completion Date
March 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Qurgen Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with relapsed/refractory/intolerant to standard of care therapies, for advanced/ metastatic solid tumors.
Detailed Description
In an effort to overcome the major challenges of the conventional cancer cell-killing therapy for high side effect, drug resistance, cancer recurrence and tumor heterogenicity, Qurgen Inc. is developing a novel transcription factor (TF) protein anticancer drug, named SON-DP, to treat the Participants with relapsed and advanced metastatic solid tumors. Proposed as an effective therapeutic drug product for a cell-converting cancer therapy, SON-DP is expected to transform cancer cells in situ into normal tissue cells via a SON-DP induced cancer cell reprogramming and re-differentiation process as an innovative rationale. SON-DP is developed based on the rationale of cancer cell conversion into normal tissue cells as the primary mechanism of actions of a new cancer therapy, not by cancer cell-killing, the traditional goals of chemotherapy, radiation therapy, targeted therapy and immune therapy. Cancer cell conversion is achieved by the SON-DP induced pluripotent re-programming in situ inside tumor tissue into transient iPSCs (tiPSCs) that quickly re-differentiate into normal tissue cells induced by the differentiating resident tissue environment. The in situ generated tiPSCs either secrete exosomes, providing the embryonic stem cells (ESC)-like microenvironments to transform the surrounding cancer cells into normal tissue cells for an overall malignant phenotype reversion (OMPR) (an effect named as a bystander effect), or display a targeting effect that enables the in situ generated tiPSCs to track down the distant metastatic cancer cells for OMPR (an effect named as a tropism effect). The SON-DP-induced cell reprogramming also restored the mutation-caused and compromised p53 checkpoint in cancer cells to re-establish cell quality control system that ensures the downstream re-differentiation of the in situ generated tiPSCs into normal tissue cells. Overall, this SON-DP-induced re-programming and re-differentiation process is capable of transforming both primary and metastatic cancer cells into normal tissue cells. Preclinical studies demonstrated that treatment of tumors with SON-DP resulted in eradication of late-stage cancers and long term (over 3 years) survival without teratoma formation and cancer recurrence in multiple tumor-bearing mouse/rat (syngeneic) or human xenograft rodent models, providing high treatment efficacy of this cell-converting cancer therapy. Thus, the cell-converting cancer therapy rationale represents a new cancer therapeutic strategy. SON-DP was tolerated in tumor-bearing rodents, as well as in naïve rats, dogs, and monkeys as demonstrated by GLP-enabled (rats and dogs) and non-GLP (monkey) toxicity study and after repeated IV administrations at higher doses compared with the planned clinical dose range. Therefore, the current nonclinical studies, including pharmacodynamics (PD), pharmacokinetics (PK) and toxicology studies, support the safety and efficacy of SON-DP TF protein drug product to be used in clinical studies of human participants. This first-in-human (FIH) clinical study will be conducted in selected types of relapsed/refractory advanced/metastatic solid tumors as a step in demonstrating the utility of this anticancer agent. In this SON-DP-A001-ST clinical trial, SON-DP is given to the participants with late stage solid tumors through 90-minutes IV infusion either once a week or twice a week at first 4 dose levels during the first Phase I dose escalation stage with the purpose to identify the final schedule (either once a week or twice a week) for the last 3 higher dose levels and the recommended phase II dose (RP2D) for the second Phase Ib does expansion stage that will focus on 4 cancer types including breast cancer, pancreatic cancer, ovarian cancer and colorectal cancer. During Phase Ia dose escalation stage, an accelerated 3+3 design will be followed. A Safety Monitoring Committee (SMC) will be formed to evaluate all the safety, efficacy, pharmacokinetic and pharmacodynamic data of each dose level cohort to decide if the SON-DP dose level should be either escalated to the next dose level or de-escalated to one level below or determination of maximum tolerated dose (MTD) or RP2D confirmation or others. Phase Ia will enroll the participants with various types of solid tumors that metastasized and not response to standard treatment. During Phase Ib dose expansion stage, SON-DP will be used, at RP2D dose level, to treat the participants with 4 specific cancer types including breast cancer, pancreatic cancer, ovary cancer or colorectal cancer. Four groups of cancer cohorts will be opened with eligible participants who have relapsed/refractory/intolerant to standard of care therapies of these four advanced/metastatic solid tumors. Participants will be followed for safety, confirmation of the RP2D, PK, PD, and anti-tumor activity as measured by standard assessment tools.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer
Keywords
SON-DP, Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Model Description
This is a first-in-human and first-in-class, open-label, Phase I clinical trial including a Phase Ia dose escalation stage for the participants with all solid tumor types using seven dose levels of SON-DP to determine the RP2D, MTD and DLT; and a Phase Ib dose expansion stage for the participants of four arms including breast cancer, pancreatic cancer, ovary cancer or colorectal cancer using the RP2D of SON-DP obtained from Phase Ia.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Dose escalation, Cohort 1
Arm Type
Experimental
Arm Description
Drug: SON-DP 1 participant or 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 1 at dose level 1 once per week in 28-day cycle, for up to 6 cycles.
Arm Title
Dose escalation, Cohort 2
Arm Type
Experimental
Arm Description
Drug: SON-DP 1 participant or 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 2 at dose level 2 once per week in 28-day cycle, for up to 6 cycles.
Arm Title
Dose escalation, Cohort 3
Arm Type
Experimental
Arm Description
Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 3 at dose level 3 once per week in 28-day cycle, for up to 6 cycles.
Arm Title
Dose escalation, Cohort 4
Arm Type
Experimental
Arm Description
Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 4 at dose level 4 once per week in 28-day cycle, for up to 6 cycles.
Arm Title
Dose escalation, Cohort 5
Arm Type
Experimental
Arm Description
Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 5 at dose level 3 twice per week in 28-day cycle, for up to 6 cycles.
Arm Title
Dose escalation, Cohort 6
Arm Type
Experimental
Arm Description
Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 6 at dose level 4 twice per week in 28-day cycle, for up to 6 cycles.
Arm Title
Dose escalation, Cohort 7
Arm Type
Experimental
Arm Description
Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 7 at dose level 5 either once per week or twice per week (FINAL SCHEDULE) in 28-day cycle, for up to 6 cycles.
Arm Title
Dose escalation, Cohort 8
Arm Type
Experimental
Arm Description
Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 8 at dose level 6 either once per week or twice per week (FINAL SCHEDULE) in 28-day cycle, for up to 6 cycles.
Arm Title
Dose escalation, Cohort 9
Arm Type
Experimental
Arm Description
Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 9 at dose level 7 either once per week or twice per week (FINAL SCHEDULE) in 28-day cycle, for up to 6 cycles.
Arm Title
Dose escalation, Cohort 10
Arm Type
Experimental
Arm Description
Drug: SON-DP Up to 12 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion at the RP2D-1 dose level using either once per week or twice per week (FINAL SCHEDULE), for up to 6 cycles.
Arm Title
Dose escalation, Cohort 11
Arm Type
Experimental
Arm Description
Drug: SON-DP Up to 12 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level using either once per week or twice per week (FINAL SCHEDULE), for up to 6 cycles.
Arm Title
Dose expansion, Arm 1
Arm Type
Experimental
Arm Description
Drug: SON-DP Up to 18 participants with breast cancer will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level using the Final Schedule, for up to 6 cycles.
Arm Title
Dose expansion, Arm 2
Arm Type
Experimental
Arm Description
Drug: SON-DP Up to 18 participants with pancreatic cancer will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level, for up to 6 cycles.
Arm Title
Dose expansion, Arm 3
Arm Type
Experimental
Arm Description
Drug: SON-DP Up to 18 participants with ovarian cancer will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level, for up to 6 cycles.
Arm Title
Dose expansion, Arm 4
Arm Type
Experimental
Arm Description
Drug: SON-DP Up to 18 participants with colorectal cancer will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level, for up to 6 cycles.
Intervention Type
Drug
Intervention Name(s)
SON-DP
Intervention Description
Solution for IV administration
Primary Outcome Measure Information:
Title
Number of participants with AEs, with abnormal vital signs, abnormal ECG readings, abnormal clinical laboratory tests results, abnormal physical examinations and abnormal ECOG performance status.
Time Frame
Up to 7 months after the first dose
Title
MTD (Maximum tolerable dose) / RP2D (Recommended dose for phase II)
Time Frame
During 28-day DLT observation period
Secondary Outcome Measure Information:
Title
ORR
Description
Objective response rate (ORR)
Time Frame
Up to 6 months after the first dose
Title
DCR
Description
Disease control rate (DCR)
Time Frame
Up to 6 months after the first dose
Title
DOR
Description
Duration of response (DoR)
Time Frame
Up to 6 months after the first dose
Title
TTP
Description
Time-to-event endpoints of time to disease progression (TTP)
Time Frame
Up to 6 months after the first dose
Title
PFS
Description
Progression-free survival (PFS)
Time Frame
Up to 6 months after the first dose
Title
OS
Description
Overall Survival (OS)
Time Frame
Time Frame: Up to 12 months after the first dose
Title
Cmax
Description
Maximum serum concentration (Cmax) of 3 proteins from SON-DP will be investigated.
Time Frame
Up to 6 months after the first dose
Title
Tmax
Description
Time to maximum serum concentration (Tmax) of 3 proteins from SON-DP will be investigated.
Time Frame
Up to 6 months after the first dose
Title
T1/2
Description
Half-life (T1/2) of 3 proteins from SON-DP will be investigated.
Time Frame
Up to 6 months after the first dose
Title
AUC0-t
Description
AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration.
Time Frame
Up to 6 months after the first dose
Title
CL
Description
Clearance (CL) in the serum of 3 proteins from SON-DP per unit of time will be investigated.
Time Frame
Up to 6 months after the first dose
Other Pre-specified Outcome Measures:
Title
SON-DP concentration in tumor biopsy tissue
Time Frame
Up to 5 weeks after the first dose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed written informed consent; Male or female participants aged ≥ 18 years; For Phase Ia: Participants with histologic diagnosis and confirmed solid tumor; For Phase Ib: Participants with one of the four tumor types: breast cancer, pancreatic cancer, ovarian cancer or colorectal cancer; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at study entry and an estimated life expectancy of at least 3 months; Agree to the placement of drug infusion venous access; For high dose group, agree for two biopsies, one at screening and one at 1st week of cycle 2; Adequate hematological function; Adequate hepatic/renal function; Acceptable coagulation function; Recovered from prior treatment Adverse Effect; Effective contraception for female participant with child bearing potential participants and sexually active male participants. Exclusion Criteria: Participation in investigational study within 2 weeks or 5 half-lives, whichever is shorter of the first dose of study treatment. Impaired cardiac function or clinically significant cardiac disease. History of stroke or clinically significant intracranial hemorrhage within 6 months before first dose of study drug. Malignant disease, other than that being treated in this study. Anticancer therapy within 5 half-lives or 2 weeks (whichever is longer) prior to study entry. Active infection requiring intravenous systemic antibiotic or antiviral therapy within 14 days prior to the first dose of study drug. Major surgery within 4 weeks of the first dose of study treatment. Any medical condition that would, in the Investigator's judgment, prevent the participant's participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jianjun Wang
Phone
+1(248)607 8451
Email
wangjianjun@qurgen.com
First Name & Middle Initial & Last Name or Official Title & Degree
Miao Xiao
Phone
+1 (647) 679 3483
Email
xiaomiao@qurgen.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Britney Winterberger
Organizational Affiliation
Tigermed America LLC.
Official's Role
Study Director
Facility Information:
Facility Name
Banner MD Anderson Cancer Center (BMDACC)
City
Gilbert
State/Province
Arizona
ZIP/Postal Code
85234
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Katt Mackin
Phone
480-256-3425
Email
Katt.Mackin@bannerhealth.com
First Name & Middle Initial & Last Name & Degree
Jason Niu
Facility Name
Henry Ford Health System
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cesar Figueras
Phone
313-433-8915
Email
cfiguer1@hfhs.org
First Name & Middle Initial & Last Name & Degree
Amy Weise
Facility Name
Carolina BioOncology Institute
City
Huntersville
State/Province
North Carolina
ZIP/Postal Code
28078
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ashley McClain Wallace
Phone
980-441-1021
Email
awallace@carolinabiooncology.org
First Name & Middle Initial & Last Name & Degree
John Powderly
Facility Name
Stephenson Cancer Center, University of Oklahoma
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christina Caldwell
Phone
405-271-8001
Ext
48171
Email
Christina-Caldwell@ouhsc.edu
First Name & Middle Initial & Last Name & Degree
Susanna Ulahannan
Facility Name
MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Siqing Fu
Phone
877-632-6789
Email
siqingfu@mdanderson.org
First Name & Middle Initial & Last Name & Degree
Jing Peng
Phone
713-792-2208
Email
jingpeng@mdanderson.org
First Name & Middle Initial & Last Name & Degree
Siqing Fu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

We'll reach out to this number within 24 hrs